The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
September 26, 2016
View Complete Issue         Table of Contents 2019 
Sebelipase Alfa (Kanuma) for Lysosomal Acid Lipase Deficiency (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Sebelipase Alfa (Kanuma) for Lysosomal Acid Lipase Deficiency (online only)
September 26, 2016 (Issue: 1504)
The FDA has approved sebelipase alfa (Kanuma – Alexion), a recombinant form of lysosomal acid lipase (LAL), for enzyme replacement therapy in patients with LAL deficiency. Sebelipase alfa is the first drug to be approved in the US for treatment...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sebelipase Alfa (Kanuma) for Lysosomal Acid Lipase Deficiency (online only)
Article code: 1504c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.